Solara Active Peer Comparison

NSE: SOLARA | BSE: 541540

₹656.60

₹-6.05 (-0.91%)

As on 13-Oct-2026IST

Market cap

₹3,169 Cr

Revenue (TTM)

₹1,431 Cr

P/E Ratio

P/B Ratio

2.5

Div. Yield

0 %

Edit

	Solara Active	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	3,169	35,437	26,111	16,518	14,314
Revenue (₹ Cr)	1,431	9,683	2,372	2,590	1,108
Net Profit (₹ Cr)	-1.62	1,018.97	497.77	603.02	270.18
Net Margin (%)	-0.11	10.47	20.72	22.63	23.29
RoE (%)	0.34	21.30	28.49	19.61	14.45
Price to Earnings	--	35.04	52.46	27.39	51.98
Price-To-Book	2.49	6.77	12.92	4.74	6.90

Income Statement (₹ Cr)

	Solara Active	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	1,431.43	9,683.45	2,371.81	2,590.40	1,108.39
Total Income	1,439.30	9,730.84	2,402.61	2,664.23	1,159.90
Total Expenditure	1,239.73	7,739.53	1,608.91	1,753.71	720.01
EBITDA	191.70	1,943.92	762.90	836.69	388.38
Depreciation	102.81	425.10	98.11	78.88	74.78
EBIT	88.89	1,518.82	664.79	757.81	313.60
Interest	92.49	148.45	26.33	5.43	0.26
Other Income	7.87	47.39	30.80	73.83	51.50
Exceptional Items	-5.89	-27.85	0.00	-25.66	-3.28
Profit before Tax	-1.62	1,389.91	669.26	800.55	361.56
Provision for Tax	0.00	370.94	171.48	197.53	91.39
Profit after Tax	-1.62	1,018.97	497.77	603.02	270.18

	Solara Active	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	1,252.88	4,950.03	1,874.47	3,332.13	2,017.06
Minority Interest	0.00	-7.58	0.00	0.00	2.51
Non-Current Liabilities	183.13	723.57	345.47	142.73	50.51
Current Liabilities	893.91	3,912.24	710.20	508.04	169.08
Total Liabilities	2,332.59	9,514.48	2,930.14	4,157.10	2,231.79

	Solara Active	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	1,386.69	3,392.16	1,290.62	1,321.38	957.22
Current Assets	858.10	5,612.10	1,483.13	2,649.36	1,250.11
Total Assets	2,332.59	9,514.48	2,930.14	4,157.10	2,231.79
Total Debt*	664.54	1,204.08	196.61	0.00	0.00
Net Current Assets	-35.81	1,699.86	772.93	2,141.33	1,081.04
Contingent Liabilities	563.73	258.92	13.18	4.82	3.76

	Solara Active	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	152.91	943.55	346.68	565.41	266.88
Cash Flow from Investing Activities	-98.83	-1,193.06	-423.73	-570.15	-142.72
Cash from Financing Activities	-53.55	343.43	20.98	-64.34	-112.88
Net Cash Inflow / Outflow	0.53	93.92	-56.08	-69.08	11.28

	Solara Active	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	4.61	25.25	27.50	24.61	18.04
ROE (%)	0.34	21.30	28.49	19.61	14.45
ROA (%)	-0.07	11.42	19.48	16.31	12.66
EBIT Margin (%)	6.21	15.68	28.03	29.25	28.29
Net Margin (%)	-0.11	10.47	20.72	22.63	23.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Solara Active	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	15.49	18.36	78.33	7.93	-6.72
EBIT Growth (%)	-28.09	30.43	303.07	19.88	-26.64
Net Profit Growth (%)	-106.61	32.39	182.61	21.66	-24.38
EPS Growth (%)	-82.74	36.68	277.72	25.42	-21.99
Book Value Growth (%)	14.35	11.36	22.95	18.43	11.27

	Solara Active	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	745.93	34.32	52.46	26.52	51.52
Price / Book Value	2.49	6.77	12.92	4.74	6.90
Dividend Yield (%)	0.00	0.19	0.17	0.37	0.55
EV/EBITDA	19.72	18.77	34.02	18.81	35.78
Market Cap (₹ Cr)	1,891.93	30,257.56	15,412.11	11,956.86	10,627.92

	Solara Active	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.09	0.05	0.09	0.00	0.00
Short term debt to equity ratio	0.40	0.16	--	--	--
Current Ratio	0.96	1.43	2.09	5.21	7.39
Quick Ratio	0.60	0.82	1.37	3.85	5.46
Interest Coverage	0.98	10.36	26.41	148.49	1,386.30

	Solara Active	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	30.65	26.46	22.82	41.42	41.52
Asset Turnover	0.63	1.09	0.93	0.70	0.52
Receivable days	98.65	88.68	77.32	144.58	169.86
Inventory Days	81.95	84.11	80.83	96.67	97.92
Payable days	139.04	176.65	125.94	135.45	159.68
Cash Conversion Cycle	41.56	-3.86	32.22	105.80	108.11

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.